Exploring the Use of PITO-Bruhneb in CLL and Richter's Syndrome

The treatment landscape of chronic lymphocytic leukemia (CLL) has transformed over the years with the increased use of Bruton’s tyrosine kinase (BTK) inhibitors, which have demonstrated promising results in several clinical trials.

In this podcast, leading experts Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Catherine Coombs, MD, UC Irvine Health, Orange, CA, discuss key updates in CLL, including the changing role of chemotherapy in the era of novel agents, the promise of next-generation BTK inhibitors, and more. This discussion took place at the 10th Annual Meeting of the Society of Hematologic Oncology (SOHO), which was held in Houston, TX, from September 28-October 1.

The post Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more appeared first on VJHemOnc.